Back to Search Start Over

Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients

Authors :
Gabriel Fernández
José Ferro
María Veloso
Marta Dragosky
Nazario Boido
Ramiro Fernández
Liliana Franco
Sandra Zirone
Roberto Albina
Victoria Lanza
Susana S. Meschengieser
Hugo Medici
Nicolás Fernández Escobar
Lucia Barazzutti
Graciela Elena
Andrea Schenone
José Luis Saavedra
Analía Carvani
Greogorio Buchovsky
Luis Aversa
Alejandra Cedola
David Verón
Katja Muller
Nora Watman
Beatriz Girardi
Marcela Corrales
Graciela Galván
Marcelo Contte
Angie Barbieri María
Gabriela Nuñez
Luis Quiroga
Gabriela Aguilar
Alba Ruiz
Julieta Bietti
Marisa Marquez
Lucía Richard
Hugo Robledo
Paola Reichel
Graciela Zárate
Leonardo Feldman
María Fernanda Cuello
Sergio Gómez
Victoria Welsh
Francis Del Río
Mario Savarino
María Á Lvarez Bollea
María Silvia Larroude
Andrés Marino
Marcela Aznar
Moira Bolesina
Cristina Cabral Castella
S Ernesto Veber
Gustavo Kantor
Patricia De Ambrosio
Daniel Bar
Adriana Degano
Alba Sanabria
Viviana Bacciedoni
Norberto Guelbert
Rubén Colimodio
María Nucifora
Marcelo Pujol
Adriana Arizo
Alcyra Fynn
Germán Damiani
Nora Basack
Juan José Chain
Bárbara Soberón
Graciela Pujal
María Brun
Sandra Borchichi
Gisela Nisnovich
Rossana Jaureguiberry
Gustavo Carro
Marina Szlago
Hugo Donato
Alejandra Maro
Ccecilia Baduel
Blanca Diez
María Cristina Rapetti
Isabel Pacheco
Maura Papucci
Guillermo Drelichman
Maya Schweri
Ignacio Fernández
Source :
American Journal of Hematology. 91:E448-E453
Publication Year :
2016
Publisher :
Wiley, 2016.

Abstract

Patients with Gaucher type 1 (GD1) throughout Argentina were enrolled in the Argentine bone project to evaluate bone disease and its determinants. We focused on presence and predictors of bone lesions (BL) and their relationship to therapeutic goals (TG) with timing and dose of enzyme replacement therapy (ERT). A total of 124 patients on ERT were enrolled in a multi-center study. All six TG were achieved by 82% of patients: 70.1% for bone pain and 91.1% for bone crisis. However, despite the fact that bone TGs were achieved, residual bone disease was present in 108 patients on ERT (87%) at time 0. 16% of patients showed new irreversible BL (bone infarcts and avascular osteonecrosis) despite ERT, suggesting that they appeared during ERT or were not detected at the moment of diagnosis. We observed 5 prognostic factors that predicted a higher probability of being free of bone disease: optimal ERT compliance; early diagnosis; timely initiation of therapy; ERT initiation dose ≥45 UI/kg/EOW; and the absence of history of splenectomy. Skeletal involvement was classified into 4 major phenotypic groups according to BL: group 1 (12.9%) without BL; group 2 (28.2%) with reversible BL; group 3 (41.9%) with reversible BL and irreversible chronic BL; and group 4 (16.9%) with acute irreversible BL. Our study identifies prognostic factors for achieving best therapeutic outcomes, introduces new risk stratification for patients and suggests the need for a redefinition of bone TG. Am. J. Hematol. 91:E448-E453, 2016. © 2016 Wiley Periodicals, Inc.

Details

ISSN :
03618609
Volume :
91
Database :
OpenAIRE
Journal :
American Journal of Hematology
Accession number :
edsair.doi...........55101e208e6121576c2a830916bc5e9c
Full Text :
https://doi.org/10.1002/ajh.24486